Early stage breast cancer treatment and prognostic factors

Suppan, Christoph; Balić, Marija

doi:10.1007/s12254-017-0328-2

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Without timely treatment, breast cancer easily metastasize to heart, brain, lung and other important organs, posing a serious threat to human life and health (4). The survival rate of breast cancer patients has improved due to the continuous progress of surgical treatment, radiotherapy and chemotherapy and the wide application of molecular targeting and immunotherapy, but there are still approximately 20-30% of patients who relapse and develop distant metastasis (5)(6)(7). The study of biomarkers can predict the risk and metastasis of malignant tumors, which is helpful for the treatment of breast cancer (8).…”

Section: Introductionmentioning

confidence: 99%

Expression of Krüppel-like factor 9 in breast cancer patients and its effect on prognosis

Jiang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Expression of Krüppel-like factor 9 (KLF9) in breast cancer tissue and its influence on prognosis was investigated. Sixty-eight patients with breast cancer admitted in Ningde Hospital Affiliated to Fujian Medical University from February 2014 to August 2015 were collected, and the expression level of KLF9 in cancerous tissue (n=68) and normal tissue (n=68) of the patients was measured by quantitative real-time PCR (RT-qPCR). The relationship between the expression and clinical pathological features and prognosis of patients was analyzed. The expression level of KLF9 in cancerous tissue was significantly lower than that in normal tissue (P<0.05). The expression in breast cancer tissue was not significantly correlated with age, height, menstrual status, lymph node metastasis or pathological differentiation (P>0.05), but was significantly correlated with tumor size and clinical stage (P<0.05). The 1-, 2-, and 3-year survival rates in the high expression group were significantly higher than those in the low expression group (P<0.001). Univariate Cox regression analysis was carried out according to the 3-year survival of the patients, and the results showed that tumor size (P= 0.009), lymph node metastasis (P= 0.002), pathological differentiation (P=0.015), clinical stage (P=0.013), and KLF9 (P=0.018) were factors affecting the survival of breast cancer patients. Subsequently, multivariate Cox regression analysis of the indicators with differences showed that those indicators were independent predictors of survival of breast cancer patients. In conclusion, KLF9 expression is low in breast cancer tissue, and its expression level is related to tumor size and clinical stage. Moreover, tumor size >5 cm, lymph node metastasis, low pathological differentiation, high clinical stage and low expression of KLF9 are all important factors that cause death of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Expression of Krüppel-like factor 9 in breast cancer patients and its effect on prognosis

Jiang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Regarding systemic treatment in the adjuvant setting, Marija Balic [2] presents three prospective trials using extended endocrine therapy (DATA, IDEAL, NS-ABP-B42) with unexpected results, at least for some of us. The use of bisphosphonates in adjuvant therapy has been addressed in the TEAMIIb trial and Balic also presents data of patients with HER2-enriched breast cancer in the neoadjuvant (NSABP-B52; standard treatment with or without endocrine therapy) and in an adjuvant setting (only stage I; APT trial using paclitaxel weekly as backbone as well as adjuvant TDM1 versus trastuzumab using pertuzumab in both groups).…”

mentioning

confidence: 99%

Post San Antonio Breast Cancer Symposium

Fitzal

2017

memo

View full text Add to dashboard Cite

The 2016 SABCS (San Antonio Breast Cancer Symposium) provided delegates with a number of interesting and some praxis-changing data. This issue of memo highlights the most relevant data from the SABCS presented by leading breast cancer experts from Austria.Locoregional issues are addressed by Michael Hubalek [1]. He presents data regarding sentinel node biopsy after neoadjuvant therapy from the GANEA trial in patients with clinical node-negative disease. Then Hubalek shows data with a protease-activatable radiometric fluorescent peptide dye conjugate (AVB-620) to identify malignant tissue intraoperatively and a poster from Denmark showing data of radioisotopic seed localisation technique for nonpalpable lesions. There were new interesting data regarding radiotherapy and breast reconstruction and a study regarding MRI for surgical planning.Regarding systemic treatment in the adjuvant setting, Marija Balic [2] presents three prospective trials using extended endocrine therapy (DATA, IDEAL, NS-ABP-B42) with unexpected results, at least for some of us. The use of bisphosphonates in adjuvant therapy has been addressed in the TEAMIIb trial and Balic also presents data of patients with HER2-enriched breast cancer in the neoadjuvant (NSABP-B52; standard treatment with or without endocrine therapy) and in an adjuvant setting (only stage I; APT trial using paclitaxel weekly as backbone as well as adjuvant TDM1 versus trastuzumab using pertuzumab in both groups). Balic also shows a poster from the MINDACT trial comparing immunohistochemical with genomic subtype classification suggesting that the KI67 might

show abstract

Racial differences in genomic testing and receipt of endocrine therapy in early-stage breast cancer

Qureshi

Oladeru

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

Early stage breast cancer treatment and prognostic factors

Cited by 3 publications

References 23 publications

Expression of Krüppel-like factor 9 in breast cancer patients and its effect on prognosis

Expression of Krüppel-like factor 9 in breast cancer patients and its effect on prognosis

Post San Antonio Breast Cancer Symposium

Racial differences in genomic testing and receipt of endocrine therapy in early-stage breast cancer

Contact Info

Product

Resources

About